Jeffrey A. Meckler - 11 Feb 2026 Form 4 Insider Report for Indaptus Therapeutics, Inc. (INDP)

Signature
/s/ Jeffrey Meckler
Issuer symbol
INDP
Transactions as of
11 Feb 2026
Net transactions value
$0
Form type
4
Filing time
13 Feb 2026, 16:15:18 UTC
Previous filing
29 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Meckler Jeffrey A Co-Chief Executive Officer, Director C/O INDAPTUS THERAPEUTICS, INC, 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK /s/ Jeffrey Meckler 13 Feb 2026 0001506916

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INDP Warrants (right to buy) Disposed to Issuer -3,033 -100% 0 11 Feb 2026 Common Stock 3,033 $47.60 Direct F1
transaction INDP Warrants (right to buy) Award +3,033 3,033 11 Feb 2026 Common Stock 3,033 $1.75 Direct F1
transaction INDP Warrants (right to buy) Disposed to Issuer -1,519 -100% 0 11 Feb 2026 Common Stock 1,519 $29.40 Direct F1
transaction INDP Warrants (right to buy) Award +1,519 1,519 11 Feb 2026 Common Stock 1,519 $1.75 Direct F1
transaction INDP Warrants (right to buy) Disposed to Issuer -12,136 -100% 0 11 Feb 2026 Common Stock 12,136 $8.30 Direct F1
transaction INDP Warrants (right to buy) Award +12,136 12,136 11 Feb 2026 Common Stock 12,136 $1.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.

Remarks:

On June 26, 2025, the Company effected a 1-for-28 reverse stock split (the "Reverse Stock Split") of the Company's common stock. All amounts have been adjusted to give effect to the Reverse Stock Split.